The drugmaker said it would report to the FDA any “credible allegation” of data-manipulation within five business days of learning about it.
The move comes after a recent scandal in which the drugmaker did not report manipulated data in its application for its $2.1 million gene therapy drug Zolgensma until after it was approved by the agency.
Novartis made the promise publicly at an investor meeting Sept. 9, though they already made the commitment to the FDA last month as part of a formal response to the FDA’s investigation.
The FDA has threatened to file civil and criminal charges against Novartis for failing to report the data until after the drug’s approval.
Agency officials said Zolgensma still appears safe and effective and would have been approved anyway, STAT reported.
Read the full report here.
More articles on pharmacy:
Civica Rx says it isn’t afraid of competition
Cigna rolls out plan to fully cover expensive gene therapies
Rutgers to close 3 on-campus pharmacies
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
